How does lurbinectedin's use impact pregnancy outcomes?

How does lurbinectedin's mechanism affect fetal development?

Lurbinectedina works by binding the DNA minor groove and disrupting transcription in rapidly dividing cells. In animal models this activity has been linked to increased rates of fetal loss and structural malformations when the drug is given during organogenesis.

What pregnancy data exist in humans?

No controlled studies track outcomes in pregnant patients. Product labeling states lurbinectedina is contraindicated in pregnancy because of the mechanism-based risk seen in animals. Case reports are limited to accidental exposure or off-label use; these reports describe spontaneous abortion or termination but do not establish incidence.

Can lurbinectedina be used safely in women planning pregnancy?

Women of childbearing potential are advised to use effective contraception during treatment and for at least six months after the last dose. Male partners should continue contraception for four months post-treatment because of the potential for genotoxic effects on sperm.

When does the pregnancy contraindication end after therapy?

The six-month contraception window after the final dose is based on the drug's half-life and the estimated time for clearance of residual genotoxic metabolites.

What monitoring is recommended if exposure occurs?

If a woman becomes pregnant while receiving or shortly after lurbinectedina, immediate consultation with a maternal-fetal medicine specialist is advised. Ultrasound surveillance for structural anomalies and genetic counseling are standard steps; decisions about continuation rest with the clinical team and patient.

How do regulators classify lurbinectedina for pregnancy risk?

The FDA assigns the drug Pregnancy Category D. This designation reflects positive evidence of human fetal risk, but potential benefits may warrant use in life-threatening situations where safer alternatives are unavailable.

Who manufactures lurbinectedina and what patent protections apply?

Pharma Mar holds the reference listed drug rights. Current U.S. Orange Book listings show composition-of-matter and use patents extending into the late 2020s. Biosimilar or generic entry before patent expiry would require successful patent challenges or design-around strategies.

[1] https://www.drugpatentwatch.com/drug/lurbinectedin